conivaptan (vaprisol) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Conivaptan is an arginine vasopressin (AVP) receptor antagonist with affinity for AVP receptor subtypes V1A and V2. The antidiuretic action of AVP is mediated through activation of the V2 receptor, which functions to regulate water and electrolyte balance at the level of the collecting ducts in the kidney. Conivaptan was approved in 2004 for hyponatremia caused by syndrome of inappropriate antidiuretic hormone. Conicaptan is being evaluated for reduce intracranial pressure in patients with traumatic brain injury, and as a treatment for heart failure.   NCATS

Chemistry

  • SMILES: Cc1nc2c([nH]1)-c1ccccc1N(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)CC2
  • InChIKey: IKENVDNFQMCRTR-UHFFFAOYSA-N
  • Mol. Mass: 498.59
  • ALogP: 6.51
  • ChEMBL Molecules:
    conivaptan  
    conivaptan hydrochloride  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$340.3400
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(1,1'-biphenyl)-2-carboxamide, n-(4-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1h)-yl)carbonyl)phenyl)- | (1,1'-biphenyl)-2-carboxamide, n-(4-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1h)-yl)carbonyl)phenyl)-, monohydrochloride | 4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1h)-yl)carbonyl)-2-biphenylcarboxanilide | 4''-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1h)-yl)carbonyl)-2-biphenylcarboxanilide | ci-1025 | conivaptan | conivaptan hcl | conivaptan hydrochloride | vaprisol | ym087 | ym 087 | ym-087

Organizations (14)

Research & Development (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (2)


 

Heart Failure

Hyponatremia (approved 2005)

Experimental Indications - Clinical Trial Phases 1-4 (11)


 

Blood Volume (Phase 4)

Body Fluids (Phase 4)

Brain Edema (Phase 2)

Brain Injuries, Traumatic (Phase 1)

Cerebrovascular Trauma (Phase 1)

Heart Failure (Phase 4)

Hyponatremia (Phase 4)

Kidney Diseases (Phase 1)

Liver Cirrhosis (Phase 2)

Liver Diseases (Phase 1)

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 21
  • # of Trial Organizations: 14

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue